section name header

Pronunciation

moe-KLOE-be-mide

Classifications

Therapeutic Classification: antidepressants

Pharmacologic Classification: monamine oxidase inhibitors, benzamides

Indications

REMS


Action

  • Short-acting, reversible inhibitor of monoamine oxidase type A.
  • Increases concentrations of serotonin, norepinephrine, and dopamine.
Therapeutic effects:
  • Decreased symptoms of depression, with improved mood and quality of life.

Pharmacokinetics

Absorption: 98% absorbed following oral administration, but undergoes first-pass hepatic metabolism resulting in 90% bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Extensively metabolized (partially by CYP2C19 and CYP2D6), very small amounts are pharmacologically active, less than 1% excreted unchanged in urine.

Half-Life: 1.5 hr ( with dose).

Time/Action Profile

ROUTEONSETPEAKDURATION
POdays–several wk (antidepressant effect)0.5–3.5 hr (blood levels)24 hr (MAO-A inhibition)



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CNS: agitation, insomnia, restlessness, SUICIDAL IDEATION, tremor

CV: hypotension

Interactions

Drug-drug:

Route/Dosage

Hepatic Impairment

Availability

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

Canadian Brand Names

Manerix